The latest announcement is out from Glaukos (GKOS). Glaukos Corporation is set to share an Investor Presentation in upcoming sessions with investor…

Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared to a 1.02% decline for the Russell 3000 Health Care Index (benchmark) and a 3.22% gain for the Russell […]

Glaukos Corporation (NYSE: GKOS ) reported second-quarter 2024 adjusted loss of 52 cents per share, in line with the Zacks Consensus Estimate. The figure was narrower than the year-ago quarter''s adjusted loss of 55 cents per share. The GAAP loss per share was $1.06 compared with the prior-year quarter''s reported loss of 68 cents. Revenue Details Glaukos registered revenues of $95.7 million in the second quarter, up 19% year over year on a reported basis and 20% at constant currency (cc). The figure also surpassed the Zacks Consensus Estimate by 8.2%. Quarter in Detail The company recorded net sales of $75.9 million and $19.8 million for Glaucoma and Corneal Health, respectively, up 23% and 7% year over year. Margin Trend Gross profit increased 21.3% to $73.1 million. The adjusted gross margin was flat year over year at 82%. Selling, general and administrative expenses rose 25% to $66.2 million. Research and development expenses totaled $34.4 million, up 4% year over year. Total operating expenses were $104.4 million, up 17.6% from that recorded in the prior-year period.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Morgan Stanley raised the price target for Zeta Global Holdings Corp . (NYSE: ZETA ) from $18 to $30. Morgan Stanley analyst Elizabeth Porter downgraded the stock from Overweight to Equal-Weight. Zeta Global shares rose 2.1% to close at $21.42 on Wednesday. See how other analysts view this stock . Needham boosted the price target for Glaukos Corporation (NASDAQ: GKOS ) from $131 to $137. Needham analyst David Saxon maintained a Buy rating. Glaukos shares fell 0.6% to close at $117.17 on Wednesday. See how other analysts view this stock. B of A Securities increased Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) price target from $11 to $24. B of A Securities analyst Alec Stranahan upgraded the stock from Underperform to Buy. Day One Biopharmaceuticals shares fell 5.8% to close at $14.31 on Wednesday.

Glaukos (NYSE: GKOS ) just reported results for the second quarter of 2024. Glaukos reported earnings per share of -52 cents. This was below the analyst estimate for EPS of -51 cents. The company reported revenue of $95.69 million. This was 7.65% better than the analyst estimate for revenue of $88.89 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .

Glaukos Corporation (NYSE:NYSE:GKOS) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ETCompany ParticipantsChris Lewis - VP, IR and Corporate…

DelveInsight''s "Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast Jetzt den vollständigen Artikel lesen

Glaukos Corporation (NYSE: GKOS ) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry''s 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame. Glaukos, with a market capitalization of $5.91 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 1.3% for 2024, followed by 43.1% growth in 2025, and expects to maintain its strong performance in terms of revenues as well. The company has a trailing four-quarter average negative earnings surprise of 4.74%. Image Source: Zacks Investment Research Key Catalysts In 2023, Glaukos witnessed sales returning to growth after experiencing a downturn in 2022. This positive shift can be attributed to a more favorable macroeconomic climate and the introduction of a series of new products in recent quarters.

Glaukos (GKOS) shares rallied 3.7% in the last trading session to close at $116.66. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…